menu search

Gbpusd weekly analysis – june 4, 2023

The GBPUSD currency pair has entered a phase of consolidation following the previous uptrend from 1.035...

June 4, 2023, 3:36 am

Cogent biosciences announces positive lead-in data from ongoing phase 3 peak trial evaluating bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (gist)

– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% ...

June 3, 2023, 6:15 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...

June 3, 2023, 1:00 pm

Allogene therapeutics presents updated allo-501/501a phase 1 data in large b cell lymphoma at the american society of clinical oncology (asco) annual meeting

Long Term Follow Up Data from phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR ...

June 3, 2023, 1:00 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...

June 3, 2023, 1:00 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...

June 3, 2023, 1:00 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...

June 3, 2023, 1:00 pm


Search within

Pages Search Results: